Canada markets closed
  • S&P/TSX

    20,179.81
    +187.93 (+0.94%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CAD/USD

    0.7830
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • BTC-CAD

    31,488.15
    +674.49 (+2.19%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • RUSSELL 2000

    2,016.62
    +41.36 (+2.09%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • NASDAQ

    13,047.19
    +267.27 (+2.09%)
     
  • VOLATILITY

    19.53
    -0.67 (-3.32%)
     
  • FTSE

    7,500.89
    +34.98 (+0.47%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • CAD/EUR

    0.7627
    +0.0039 (+0.51%)
     

Charles River Laboratories to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WILMINGTON, Mass., November 16, 2021--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at two upcoming investor conferences, including:

  • Jefferies London Healthcare Conference on Thursday, November 18th, with a pre-recording of the presentation available starting at 8:00 a.m. GMT (3:00 a.m. ET); and

  • Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1st, at 9:40 a.m. ET.

Management will present an overview of Charles River’s strategic focus and business developments.

A webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each event and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005084/en/

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting